in vitro News and Research

RSS

New Life Agency announces creation of nation's first IVF insurance program

New Life Agency, Inc. today announced that it has joined forces with New Jersey-based The Diamond Institute IVF Center and Walgreens Specialty Pharmacy to create the nation's first IVF insurance program. The Assisted Reproduction Care (ARC) Insurance Program(SM) offers patients suffering from infertility feasible financial solutions for the ever-rising costs of In Vitro Fertilization (IVF) treatments, procedures and fertility medications.

20 Jan 2010

Gently rocking embryos during IVF may improve success rates

Gently rocking embryos while they grow during in vitro fertilization (IVF) improves pregnancy rates in mice by 22 percent, new University of Michigan research shows. The procedure could one day lead to significantly higher IVF success rates in humans.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

iWorx launches a family of cardiovascular research products

iWorx, a developer of advanced physiology research and teaching tools, has launched a family of cardiovascular research products used to assess cardiac performance and hemodynamics, both in vivo and in vitro.

20 Jan 2010

Findings pave way for designing better antibiotics to target bacterial transcription machinery

A new study led by researchers at NYU Langone Medical Center is shedding new light on the action of Rho, a key regulatory protein in E. coli and many other bacteria.

19 Jan 2010

New procedure could lead to higher IVF success rates in humans

19 Jan 2010

Babraham Institute research may lead to new means of making purified T cells

Research from the Babraham Institute, reported today in the Journal of Experimental Medicine, provides new insights into how our immune system produces T cells, a type of white blood cell that is an essential part of the body's immune surveillance system for fighting infection. The findings pave the way for a new means of making purified T cells, which gets over one of many hurdles faced in the use of T cells in regenerative medicine and transplantations, and in addition will open up new avenues of research and applications in drug and toxicity testing in industry.

18 Jan 2010

Bone marrow transplantation survivors can father children: new study says

Men who were previously deemed sterile due to aggressive cancer treatments may still be able to biologically father children according to a new study published in the journal, Bone Marrow Transplantation.

18 Jan 2010

Fertility drugs cause a high percentage of multiple births; contribute to growing crisis of prematurity

The widespread use of so-called fertility drugs, not just high-tech laboratory procedures, likely plays a larger role than previously realized in the growing problem of premature births in the United States, because these drugs cause a high percentage of multiple births, the March of Dimes said today.

18 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

Life Technologies to acquire AcroMetrix

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire AcroMetrix, for an undisclosed amount.

12 Jan 2010

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

Stem cell therapy holds promise as potential alternative to bone grafting operations

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

Mango effective against colon and breast cancer

Mango. If you know little about this fruit, understand this: It's been found to prevent or stop certain colon and breast cancer cells in the lab.

12 Jan 2010

New therapeutic treatment may provide a potential alternative to bone grafting operation

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

Quidel to acquire Diagnostic Hybrids for $130M

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today the signing of a definitive agreement to acquire privately held Diagnostic Hybrids, Inc. for approximately $130 million in cash.

10 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

LehmanMillet honored with four prestigious industry awards

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.

9 Jan 2010

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

The Cystinosis Research Foundation of Irvine, Calif., announced it awarded $1.75 million in 11 new grants to researchers in the United States, Canada, Belgium and Italy who are working to find a cure for cystinosis, a rare, deadly metabolic and genetic disease that afflicts about 500 children and young adults in the U.S. and 2,000 worldwide.

7 Jan 2010

Prolias acquires UMBI's technology to develop human therapeutic antibodies

Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI).

7 Jan 2010

in vitro News and Research

New Life Agency announces creation of nation's first IVF insurance program

Gently rocking embryos during IVF may improve success rates

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

iWorx launches a family of cardiovascular research products

Findings pave way for designing better antibiotics to target bacterial transcription machinery

New procedure could lead to higher IVF success rates in humans

Babraham Institute research may lead to new means of making purified T cells

Bone marrow transplantation survivors can father children: new study says

Fertility drugs cause a high percentage of multiple births; contribute to growing crisis of prematurity

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Life Technologies to acquire AcroMetrix

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

Stem cell therapy holds promise as potential alternative to bone grafting operations

Mango effective against colon and breast cancer

New therapeutic treatment may provide a potential alternative to bone grafting operation

Quidel to acquire Diagnostic Hybrids for $130M

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

LehmanMillet honored with four prestigious industry awards

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

Prolias acquires UMBI's technology to develop human therapeutic antibodies

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News